SARS-CoV-2 (COVID-19) Coronavirus, Genotyping
SARS-CoV-2 is the seventh known coronavirus causing respiratory infection in humans, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. Based on its genome sequence, SARS-CoV-2 is a positive-sense, single-stranded RNA coronavirus (+ssRNA) belongs to the 2B group of the betacoronavirus family, which is the same family as SARS-CoV and MERS-CoV and has 70% similarity in genetic sequence to SARS. Each SARS-CoV-2 virion is approximately 50–200 nanometers in diameter and composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N); the N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. Its spike protein has sufficient affinity to the angiotensin-converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry.
SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the 2019–20 coronavirus outbreaks a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020. Symptoms of COVID-19 range from mild fever, cough, and shortness of breath, muscle pain, diarrhea, and sore throat to pneumonia and multi-organ failure. The disease is transmitted from human-to-human by close contact, via respiratory droplets generated by sneezing and coughing. It may also spread when one touches a contaminated surface and then their face. The incubation period appears to be 2-14 days.
The SARS-CoV-2 virus has mutated over time, resulting in genetic variation in the population of circulating viral strains over the course of the COVID-19 pandemic. The viral mutation or genetic mutation of the SARS-CoV-2 virus is a change in the genetic sequence of the SARS-CoV-2 virus when compared with a reference sequence such as Wuhan-Hu1 (the first genetic sequence identified) or USA-WA1/2020 (the first identified in the United States). The viral genome mutations related to different agents and factors such as viral replication enzymes, host enzymes, recombination events, spontaneous nucleic acid damages, and particular genetic elements are liable for generating new variants. A growing list of specific mutations that either independently, or in conjunction with other mutations are associated with increased transmissibility, disease severity, reduced treatment efficacy, or potential for vaccine failure. Genome sequencing, SNP calling, and phenotyping provide an efficient means to study the epidemiology of COVID-19 and infer the relationship between SARS-CoV-2 protein structures and COVID-19 pathogenicity.
- Evaluate the new SARS-CoV-2 virus variant pathogenicity and severity of infection
- Monitoring the vial mutation and epidemiology of the new variants
- Monitoring new variants to current and/or future vaccines to SARS-CoV-2
The presence of the new variant(s) will be matched to the government database and will help to manage the infection, severity of disease and management It can help on monitoring the epidemics and behaver of the virus in overall population.
Not Detected (Negative)
Nasopharyngeal swab, Oropharyngeal swab collected in Universal Transport Media (UTM) or Universal Viral Transport Media or UVT, Sputum.
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Diagnosis (Berl). 2021 Dec 23;9(1):11-17. [PMID: 34958184]
- Int Rev Immunol. 2022 May 28:1-22. [PMID: 35635216]
- Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917. [PMID: 31992387]
- Int J Antimicrob Agents. 2020 Feb 17:105924. [PMID: 32081636]
- J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25709. [PMID: 32056249]
- Pediatr Infect Dis J. 2005 Nov;24 (11 Suppl). [PMID: 16378050]
- Euro Surveill. 2012 Sep 27;17(39). [PMID: 23041020]
- Antivir Ther. 2007;12(4 Pt B):651-8. [PMID: 17944272]